Although R848 was originally used to study the role of antiviral and antibacterial immunity and the research on tumor has only started in recent years, several studies have shown that R848 significantly increases the number and function of CD8+ T cell and inflames the tumor immune microenvironment (TIME) (27–29). Here, CD8A is linked to neoplasm.